Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Net Income: 2022-2025

Historic Net Income for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$38.3 million.

  • Stoke Therapeutics' Net Income fell 45.09% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 138.26%. This contributed to the annual value of -$88.7 million for FY2024, which is 15.38% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Net Income is -$38.3 million, which was down 63.30% from -$23.5 million recorded in Q2 2025.
  • Over the past 5 years, Stoke Therapeutics' Net Income peaked at $112.9 million during Q1 2025, and registered a low of -$38.3 million during Q3 2025.
  • In the last 3 years, Stoke Therapeutics' Net Income had a median value of -$25.7 million in 2024 and averaged -$13.0 million.
  • Over the last 5 years, Stoke Therapeutics' Net Income had its largest YoY gain of 527.99% in 2025, and its largest YoY loss of 45.09% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Net Income (Quarterly) stood at -$25.7 million in 2022, then declined by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then tumbled by 45.09% to -$38.3 million in 2025.
  • Its Net Income was -$38.3 million in Q3 2025, compared to -$23.5 million in Q2 2025 and $112.9 million in Q1 2025.